Eric M. Dube - 31 Jan 2022 Form 4 Insider Report for Travere Therapeutics, Inc. (TVTX)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: TVTX
Reported as of: 31 Jan 2022
Net transaction value: -$131,876
SEC form: 4
Accepted by SEC: 02 Feb 2022, 15:16:28 UTC
Prior SEC filing: 26 Jan 2022
Next SEC filing: 11 Feb 2022
Source filing: View source filing
Reporting owner signature: /s/ Elizabeth E. Reed, Attorney-in-Fact

Key filing fact

Eric M. Dube filed Form 4 for Travere Therapeutics, Inc. (TVTX) on 02 Feb 2022.

Key facts

This page summarizes Eric M. Dube's Form 4 filing for Travere Therapeutics, Inc. (TVTX).
4 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 02 Feb 2022, 15:16.

Change

Previous filing in this sequence was filed on 26 Jan 2022.
Current net transaction value: -$131,876.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TVTX transaction

Common Stock

Award

Transaction value: $0
Shares: +37,848
Change %: +29%
Price: $0.000000
Shares after: 169,558
Date: 31 Jan 2022
Ownership: Direct
Footnotes: F1

TVTX transaction

Common Stock

Sale

Transaction value: $131,876
Shares: -4,813
Change %: -2.8%
Price: $27.40
Shares after: 164,745
Date: 31 Jan 2022
Ownership: Direct
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TVTX transaction Derivative

Employee stock option (right to buy)

Award

Transaction value: $0
Shares: +169,552
Change %
Price: $0.000000
Shares after: 169,552
Date: 31 Jan 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 169,552
Exercise price: $27.50
Footnotes: F3

TVTX transaction Derivative

Performance-based restricted stock units

Award

Transaction value: $0
Shares: +37,848
Change %
Price: $0.000000
Shares after: 37,848
Date: 31 Jan 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 37,848
Exercise price
Footnotes: F4, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan that are scheduled to vest over four years.

Footnote F2

The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

Footnote F3

One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.

Footnote F4

Each performance-based restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.

Footnote F5

This grant will vest upon the achievement of specified clinical/regulatory and commercial milestones, provided, however, if either vesting event occurs before the date that is 12 months after the date of grant, then the portion of the award that would have vested upon such event will instead vest on the date that is 12 months after the date of grant, and provided further that the Performance RSU will expire on January 31, 2027 to the extent the specified performance based milestones are not achieved by such date.